Blood test may predict immunotherapy success in lung and kidney cancers
NCT ID NCT06630429
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 25 times
Summary
This pilot study is testing whether changes in tumor DNA found in the blood can help doctors see if immunotherapy is working in patients with non-small cell lung cancer or kidney cancer. About 100 adults will give blood samples before and during their standard treatment. The goal is to find reliable markers that could guide treatment decisions without needing repeated tumor biopsies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA (RCC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.